Clinical Trial

PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 5, 2024 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of PM8002, a PD-L1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-15; most recent amendment 2024-12-03.
Trial Details
NCT Number NCT05918445
Lead Sponsor Biotheus Inc.
Conditions Malignant Neoplasm
Enrollment 380 participants
Start Date 2021-03-09
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-11-30 (estimated)
Updated on ClinicalTrials.gov 2024-12-05